TrialAmerican journal of hematology2012

Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies.

Brenda J Weigel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.